Cardiovascular and renal outcomes with SGLT‐2 inhibitors versus GLP‐1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta‐analysis. Here, GLP1R is linked to type 2 diabetes mellitus.